The US FDA has approved an updated label for Tremfya (guselkumab) for the treatment of active psoriatic arthritis.

Metabolic comorbidities are mechanistically intertwined with psoriasis and PsA, with obesity reducing biologic responsiveness and insulin resistance potentially sustaining joint inflammation.

Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held ...

The management of psoriatic arthritis is increasingly focused on the early identification of clinical, immunological, and ...

Early and aggressive intervention is recommended for children with juvenile idiopathic arthritis, according to new 2026 ...

The management of psoriatic arthritis is increasingly focused on the early identification of clinical, immunological, and tissue-based phenotypes predictive of therapeutic response. But there is also ...

The FDA has approved a label expansion for the interleukin-23 inhibitor guselkumab to include the inhibition of structural ...

The Department for Work and Pensions (DWP) has published the full list of 86 musculoskeletal and arthritis conditions that ...

The FDA has approved a supplemental biologics license application for the interleukin (IL)-23 inhibitor guselkumab to include evidence for the inhibition of progression of structural joint damage in ...

Tire rubber contains antioxidant chemicals, most notably 6PPD and DPPD, that are released into the air as tiny particles ...

Dandruff is one skin issue many of us are quick to self-diagnose. Not just because the symptoms seem obvious, but because we’re frequently hit with marketing for the latest, greatest treatment options ...